A Phase II Study of Ribociclib And Endocrine Treatment of Physician's Choice for Locoregional Recurrent, Resected Hormone Receptor Positive HER2 Negative Breast Cancer (RaPhLRR Study)

Project: Research

Status	Finished
Effective start/end date	12/12/23 → 12/7/24

Project Details